VCEL vs. INBX, RGNX, ITOS, ALEC, CCCC, RGEN, PCVX, EXEL, RVMD, and HALO
Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Inhibrx (INBX), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), Alector (ALEC), C4 Therapeutics (CCCC), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), and Halozyme Therapeutics (HALO). These companies are all part of the "biological products, except diagnostic" industry.
Inhibrx (NASDAQ:INBX) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk.
Vericel received 305 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 62.11% of users gave Vericel an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
Vericel has higher revenue and earnings than Inhibrx. Vericel is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
Inhibrx has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.
Inhibrx presently has a consensus target price of $27.00, indicating a potential upside of 66.15%. Vericel has a consensus target price of $46.80, indicating a potential downside of 1.89%. Given Vericel's higher probable upside, research analysts clearly believe Inhibrx is more favorable than Vericel.
Vericel has a net margin of 0.22% compared to Vericel's net margin of -13,408.95%. Inhibrx's return on equity of 0.21% beat Vericel's return on equity.
82.5% of Inhibrx shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by insiders. Comparatively, 5.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Inhibrx and Inhibrx both had 6 articles in the media. Vericel's average media sentiment score of 0.78 beat Inhibrx's score of 0.63 indicating that Inhibrx is being referred to more favorably in the media.
Summary
Vericel beats Inhibrx on 10 of the 17 factors compared between the two stocks.
Get Vericel News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
